Published in J Gastroenterol on March 30, 2013
Availability of monitoring serum HBV DNA plus RNA during nucleot(s)ide analogue therapy. J Gastroenterol (2013) 0.77
Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol (2013) 2.22
Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol (1997) 1.87
Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology (2005) 1.28
Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol (2002) 1.18
Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy. J Med Virol (2003) 0.86
Circulating hepatitis B virus nucleic acids in chronic infection : representation of differently polyadenylated viral transcripts during progression to nonreplicative stages. Clin Cancer Res (2001) 0.85
Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009. Hepatol Res (2010) 0.84
Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. Hepatology (2007) 0.81
Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. J Gastroenterol (2012) 0.80
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis (2011) 3.74
α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology (2013) 3.27
Nectin and afadin: novel organizers of intercellular junctions. J Cell Sci (2003) 3.19
Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology (2011) 3.00
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (2014) 2.83
Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. Liver Transpl (2014) 2.77
Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep (2003) 2.16
Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun (2004) 1.93
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology (2013) 1.81
Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol (2010) 1.80
Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol (2005) 1.74
Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol (2004) 1.73
Cast: a novel protein of the cytomatrix at the active zone of synapses that forms a ternary complex with RIM1 and munc13-1. J Cell Biol (2002) 1.65
Targeting lipid metabolism in the treatment of hepatitis C virus infection. J Infect Dis (2008) 1.62
Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology (2006) 1.60
A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res (2010) 1.58
Nectin: an adhesion molecule involved in formation of synapses. J Cell Biol (2002) 1.57
Nectin couples cell-cell adhesion and the actin scaffold at heterotypic testicular junctions. Curr Biol (2002) 1.55
Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha. J Infect Dis (2004) 1.55
Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology (2011) 1.52
Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology (2010) 1.44
Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS One (2012) 1.44
Effect of prostate volume on tumor grade in patients undergoing radical prostatectomy in the era of extended prostatic biopsies. J Urol (2007) 1.41
Negative regulation of intracellular hepatitis C virus replication by interferon regulatory factor 3. J Gastroenterol (2006) 1.41
Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors. Int J Urol (2014) 1.41
Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol (2006) 1.40
Association of ASIP/mPAR-3 with adherens junctions of mouse neuroepithelial cells. Dev Dyn (2002) 1.39
Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol (2008) 1.38
Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet (2011) 1.31
Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma: an analysis of 1160 cases from a nationwide survey. Ann Surg (2014) 1.25
Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology (2011) 1.24
Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology (2015) 1.24
Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res (2015) 1.23
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat (2014) 1.23
Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis. Int J Oncol (2007) 1.21
Antagonistic and agonistic effects of an extracellular fragment of nectin on formation of E-cadherin-based cell-cell adhesion. Genes Cells (2003) 1.20
Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol (2012) 1.19
Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology (2011) 1.19
Role of nectin in organization of tight junctions in epithelial cells. Genes Cells (2002) 1.18
c-Met expression in gastric cancer with liver metastasis. Oncology (2002) 1.16
Involvement of nectin in the localization of junctional adhesion molecule at tight junctions. Oncogene (2002) 1.16
Regulation of hepatitis C virus replication by interferon regulatory factor 1. J Virol (2004) 1.16
Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2. J Clin Microbiol (2007) 1.14
Surgical treatment of retroperitoneal leiomyosarcoma invading the inferior vena cava: report of three cases. Surg Today (2002) 1.13
Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res (2010) 1.13
SGIP1alpha is an endocytic protein that directly interacts with phospholipids and Eps15. J Biol Chem (2007) 1.11
Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA. Int J Urol (2011) 1.09
Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol (2011) 1.09
Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology (2014) 1.06
Role of the second immunoglobulin-like loop of nectin in cell-cell adhesion. Biochem Biophys Res Commun (2002) 1.05
Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan. Liver Int (2014) 1.05
Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology (2002) 1.04
Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis. Hepatol Res (2007) 1.03
T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. Clin Infect Dis (2005) 1.02
Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells. Clin Cancer Res (2004) 1.02
Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry (2003) 1.01
Liver Cancer Working Group report. Jpn J Clin Oncol (2010) 1.00
Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. Cancer (2013) 1.00
Chronic hepatitis delta virus infection with genotype IIb variant is correlated with progressive liver disease. J Gen Virol (2003) 1.00
Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study. Hepatol Res (2014) 1.00
Effectiveness of using fewer implanted fiducial markers for prostate target alignment. Int J Radiat Oncol Biol Phys (2009) 0.99
Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol (2009) 0.98
Value of highly sensitive fucosylated fraction of alpha-fetoprotein for prediction of hepatocellular carcinoma recurrence after curative treatment. Dig Dis Sci (2013) 0.98
Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. J Gastroenterol (2014) 0.98